ARTICLE | Clinical News
Fabrazyme agalsidase beta regulatory update
October 25, 2010 7:00 AM UTC
CHMP recommended that Fabry's disease patients resume the full recommended dose of Genzyme's Fabrazyme agalsidase beta, depending on its availability, or receive Replagal agalsidase alfa from Shire ...